THERAPIX

THERAPIX BIOSCIENCES LTD.

SPECIAL GENERAL MEETING OF SHAREHOLDERS

Notice is hereby given that the Special

General Meeting of the shareholders (the "Meeting") of Therapix Biosciences Ltd. (the "Company")

will be held at the offices of Meitar Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan 5250608, Israel, on Thursday, September

10, 2020 at 9:00 a.m. (Eastern Time) / 4:00 p.m. (Israel time).

The Meeting is being called for the following purposes:

The Board of Directors of the Company

(the "Board") recommends that you vote FOR the Proposals, which are described in the attached Proxy Statement.

The Company currently is unaware of any

other matters that may be raised at the Meeting. Should any other matters be properly raised at the Meeting, the persons designated

as proxies shall vote according to their own judgment on those matters.

Shareholders of record at the close of

trading on Monday, August 24, 2020 (the "Record Date"), are entitled to notice of and to vote at the Meeting,

either in person or by appointing a proxy to vote in their stead at the Meeting (as detailed below).

The approval of each of Proposals to be

presented at the Meeting requires the affirmative vote of holders of at least a majority of the Ordinary Shares voted in person

or presented by proxy at the Meeting.

A form of proxy for use at the Meeting

is attached to the Proxy Statement, and a voting instruction form, together with a return envelope, will be sent to holders of

American Depositary Shares representing the Company's Ordinary Shares ("ADS"). By appointing "proxies",

shareholders and ADS holders may vote at the Meeting whether or not they attend. Holders of Ordinary Shares must submit their proxies

to Mr. Oz Adler, Chief Financial Officer, at oz@therapixbio.com, if a properly executed proxy in the attached form is received by the Company at least four hours

prior to the Meeting, all of the Ordinary Shares represented by the proxy shall be voted as indicated on the form. ADS holders

should return their voting instruction form by the date set forth therein. Subject to applicable law, in the absence of instructions,

the Ordinary Shares represented by properly executed and received proxies will be voted "FOR" the proposed resolutions

to be presented at the Meeting for which the Board recommends a vote "FOR." Shareholders and ADS holders may revoke

their proxies or voting instruction form (as applicable) at any time before the deadline for receipt of proxies or voting instruction

form (as applicable) by filing with the Company (in the case of holders of Ordinary Shares) or with the Bank of New York Mellon

(in the case of holders of ADSs) a written notice of revocation or duly executed proxy or voting instruction form (as applicable)

bearing a later date.

Shareholders registered in the Company's

shareholders' register in Israel, and beneficial owners who hold their shares through members of the Tel Aviv Stock Exchange

("TASE") may also (i) vote their shares in person at the Meeting by presenting a certificate of ownership signed

by a member of the TASE which complies with the Israel Companies Regulations (Proof of Ownership of Shares for Voting at General

Meeting), 5760-2000 as proof of ownership of the shares on the Record Date, or (ii) send such certificate along with a duly executed

proxy and including a copy of their identity card, passport or certification of incorporation, as the case may be, to Mr. Oz Adler,

Chief Financial Officer, at oz@therapixbio.com, not less than 48 hours prior to the Meeting. In addition, shareholders of record

(other than the Bank of New York Mellon) can surrender their shares with the Bank of New York Mellon in order to convert such shares

to ADSs and vote as a holder of ADSs with the Bank of New York Mellon, provided such shareholders of record complete such conversion

and registration of said shares to ADSs with the Bank of New York Mellon prior to the Record Date.

ADS holders should return their proxies by the date set forth

on their form of proxy.

The Company's management will ensure that

the guidelines and instructions of the Israeli government, the Ministry of Health and local authorities are strictly implemented

during the Meeting, including with regard to gatherings and social spacing. Shareholders who wish to participate in person or through

a designated representative on their behalf are asked to follow the instructions of the Israeli authorities regarding the Covid-19

THERAPIX BIOSCIENCES LTD.

SPECIAL GENERAL MEETING OF SHAREHOLDERS

The enclosed proxy is being solicited by

the board of directors (the "Board") of Therapix Biosciences Ltd. (the "Company") for use

at the Company's Special General Meeting of shareholders of the Company (the "Meeting") to be held on

Thursday, September 10, 2020 at 9:00 a.m. (Eastern Time) / 4:00 p.m. (Israel time), or at any adjournment thereof, at the offices

of Meitar Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan 5250608. Upon the receipt of a properly executed proxy in the form

enclosed, the persons named as proxies therein will vote the ordinary shares, par value NIS 0.10 each, of the Company (the "Ordinary

Shares") covered thereby in accordance with the directions of the shareholders executing the proxy. In the absence of

such directions, and except as otherwise mentioned in this proxy statement, the Ordinary Shares represented thereby will be voted

in favor of the proposal described in this proxy statement

The record date for determining which of

the Company's shareholders is entitled to notice of, and to vote at, the Meeting is established as of the close of trading

on Monday, August 24, 2020 (the "Record Date").

INFORMATION CONCERNING VOTING

At least five shareholders who attend the

Meeting in person or by proxy who hold or represent together at least 40% of the voting rights of the Company's issued share

capital shall constitute a quorum for the Meeting. If within half an hour from the time the Meeting is convened a quorum is not

present, the adjourned meeting shall be held one week later, Thursday, September 17, 2020 at 9:00 a.m. (Eastern Time) / 4:00 p.m.

(Israel time). If a quorum is not present at the adjourned meeting within half an hour from the time appointed for such meeting,

any number of shareholders present personally or by proxy shall be deemed a quorum and shall be entitled to deliberate and to resolve

in respect of the matter for which the Meeting was convened.

You are entitled to vote at the Meeting

if you were a shareholder at the close of trading on the Record Date. Subject to the terms described herein, you are also entitled

to vote at the Meeting if you held Ordinary Shares through a bank, broker or other nominee which was a shareholder of record of

the Company at the close of trading on the Record Date or which appeared in the participant listing of a securities depository

Expenses and Solicitation

The Board is soliciting proxies for use

at the Meeting. The Company expects to mail this Proxy Statement and the accompanying proxies to ADR holders on or about September

1, 2020. In addition to solicitation of proxies to ADR holders by mail, certain officers, directors, employees and agents of the

Company, none of whom shall receive additional compensation therefor, may solicit proxies by telephone or other personal contact.

The Company shall bear the cost of the solicitation of the proxies, including postage, printing and handling and shall reimburse

the reasonable expenses of brokerage firms and others for forwarding material to beneficial owners of Ordinary Shares or holders

of American Depositary Shares ("ADS").

In accordance with the Companies Law and

regulations promulgated thereunder, any shareholder of the Company holding at least one percent of the outstanding voting rights

of the Company for the meeting may submit to the Company a proposed additional agenda item for the meeting, to Mr. Oz Adler, Chief

Financial Officer, e-mail address: oz@therapixbio.com, no later than Thursday, August 27, 2020. To the extent that there

are any additional agenda items that the Board determines to add as a result of any such submission, the Company will publish an

updated agenda and proxy card with respect to the Meeting, no later than Friday, August 28, 2020, which will be furnished

to the Commission on Form 6-K, and will be made available to the public on the Commission's website at www.sec.gov.

Required Vote and Voting Procedures

Pursuant to the Israeli Companies Law, 5799-1999, each of the

Proposals described hereinafter requires the affirmative vote of shareholders present at the Meeting, in person or by proxy, and

holding Ordinary Shares of the Company amounting in the aggregate to at least a majority of the votes actually cast by shareholders

with respect to such proposals.

THE BOARD RECOMMENDS THAT YOU VOTE "FOR"

EACH OF THE PROPOSALS.

APPROVAL OF AMENDMENTS TO THE AMENDED

AND RESTED ARTICLES OF ASSOCIATION OF THE COMPANY

Following a review carried by the Board

of certain of our charter documents, at the Meeting, shareholders will be requested to approve certain amendments of the Company's